114 related articles for article (PubMed ID: 26343594)
1. ALDH2 polymorphism, associated with attenuating negative symptoms in patients with schizophrenia treated with add-on dextromethorphan.
Lee SY; Chen SL; Chang YH; Chen PS; Huang SY; Tzeng NS; Wang LJ; Lee IH; Wang TY; Chen KC; Yang YK; Hong JS; Lu RB
J Psychiatr Res; 2015 Oct; 69():50-6. PubMed ID: 26343594
[TBL] [Abstract][Full Text] [Related]
2. Sarcosine or D-serine add-on treatment for acute exacerbation of schizophrenia: a randomized, double-blind, placebo-controlled study.
Lane HY; Chang YC; Liu YC; Chiu CC; Tsai GE
Arch Gen Psychiatry; 2005 Nov; 62(11):1196-204. PubMed ID: 16275807
[TBL] [Abstract][Full Text] [Related]
3. The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder.
Lee SY; Chen SL; Chang YH; Chen SH; Chu CH; Huang SY; Tzeng NS; Wang CL; Lee IH; Yeh TL; Yang YK; Lu RB
J Affect Disord; 2012 May; 138(3):295-300. PubMed ID: 22326841
[TBL] [Abstract][Full Text] [Related]
4. Inflammation in patients with schizophrenia: the therapeutic benefits of risperidone plus add-on dextromethorphan.
Chen SL; Lee SY; Chang YH; Chen SH; Chu CH; Tzeng NS; Lee IH; Chen PS; Yeh TL; Huang SY; Yang YK; Lu RB; Hong JS
J Neuroimmune Pharmacol; 2012 Sep; 7(3):656-64. PubMed ID: 22730040
[TBL] [Abstract][Full Text] [Related]
5. Memantine add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized, double-blind, placebo-controlled study.
Rezaei F; Mohammad-Karimi M; Seddighi S; Modabbernia A; Ashrafi M; Salehi B; Hammidi S; Motasami H; Hajiaghaee R; Tabrizi M; Akhondzadeh S
J Clin Psychopharmacol; 2013 Jun; 33(3):336-42. PubMed ID: 23609382
[TBL] [Abstract][Full Text] [Related]
6. A double-blind, placebo controlled, randomized trial of riluzole as an adjunct to risperidone for treatment of negative symptoms in patients with chronic schizophrenia.
Farokhnia M; Sabzabadi M; Pourmahmoud H; Khodaie-Ardakani MR; Hosseini SM; Yekehtaz H; Tabrizi M; Rezaei F; Salehi B; Akhondzadeh S
Psychopharmacology (Berl); 2014 Feb; 231(3):533-42. PubMed ID: 24013610
[TBL] [Abstract][Full Text] [Related]
7. Granisetron as an add-on to risperidone for treatment of negative symptoms in patients with stable schizophrenia: randomized double-blind placebo-controlled study.
Khodaie-Ardakani MR; Seddighi S; Modabbernia A; Rezaei F; Salehi B; Ashrafi M; Shams-Alizadeh N; Mohammad-Karimi M; Esfandiari GR; Hajiaghaee R; Akhondzadeh S
J Psychiatr Res; 2013 Apr; 47(4):472-8. PubMed ID: 23375406
[TBL] [Abstract][Full Text] [Related]
8. A placebo controlled study of the propentofylline added to risperidone in chronic schizophrenia.
Salimi S; Fotouhi A; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Mohammadi MR; Noorbala AA; Ahmadi-Abhari SA; Hajiazim M; Abbasi SH; Akhondzadeh S
Prog Neuropsychopharmacol Biol Psychiatry; 2008 Apr; 32(3):726-32. PubMed ID: 18096287
[TBL] [Abstract][Full Text] [Related]
9. Effects of dopamine D2 receptor Ser311Cys polymorphism and clinical factors on risperidone efficacy for positive and negative symptoms and social function.
Lane HY; Lee CC; Chang YC; Lu CT; Huang CH; Chang WH
Int J Neuropsychopharmacol; 2004 Dec; 7(4):461-70. PubMed ID: 15140279
[TBL] [Abstract][Full Text] [Related]
10. Beneficial antipsychotic effects of celecoxib add-on therapy compared to risperidone alone in schizophrenia.
Müller N; Riedel M; Scheppach C; Brandstätter B; Sokullu S; Krampe K; Ulmschneider M; Engel RR; Möller HJ; Schwarz MJ
Am J Psychiatry; 2002 Jun; 159(6):1029-34. PubMed ID: 12042193
[TBL] [Abstract][Full Text] [Related]
11. The effects of pioglitazone adjuvant therapy on negative symptoms of patients with chronic schizophrenia: a double-blind and placebo-controlled trial.
Iranpour N; Zandifar A; Farokhnia M; Goguol A; Yekehtaz H; Khodaie-Ardakani MR; Salehi B; Esalatmanesh S; Zeionoddini A; Mohammadinejad P; Zeinoddini A; Akhondzadeh S
Hum Psychopharmacol; 2016 Mar; 31(2):103-12. PubMed ID: 26856695
[TBL] [Abstract][Full Text] [Related]
12. Intranasal desmopressin as an adjunct to risperidone for negative symptoms of schizophrenia: a randomized, double-blind, placebo-controlled, clinical trial.
Hosseini SM; Farokhnia M; Rezaei F; Gougol A; Yekehtaz H; Iranpour N; Salehi B; Tabrizi M; Tajdini M; Ghaleiha A; Akhondzadeh S
Eur Neuropsychopharmacol; 2014 Jun; 24(6):846-55. PubMed ID: 24636461
[TBL] [Abstract][Full Text] [Related]
13. Efficacy of selegiline add on therapy to risperidone in the treatment of the negative symptoms of schizophrenia: a double-blind randomized placebo-controlled study.
Amiri A; Noorbala AA; Nejatisafa AA; Ghoreishi A; Derakhshan MK; Khodaie-Ardakani MR; Hajiazim M; Raznahan M; Akhondzadeh S
Hum Psychopharmacol; 2008 Mar; 23(2):79-86. PubMed ID: 17972359
[TBL] [Abstract][Full Text] [Related]
14. Association of risperidone treatment response with a polymorphism in the 5-HT(2A) receptor gene.
Lane HY; Chang YC; Chiu CC; Chen ML; Hsieh MH; Chang WH
Am J Psychiatry; 2002 Sep; 159(9):1593-5. PubMed ID: 12202283
[TBL] [Abstract][Full Text] [Related]
15. Improvement of negative and positive symptoms in treatment-refractory schizophrenia: a double-blind, randomized, placebo-controlled trial with memantine as add-on therapy to clozapine.
de Lucena D; Fernandes BS; Berk M; Dodd S; Medeiros DW; Pedrini M; Kunz M; Gomes FA; Giglio LF; Lobato MI; Belmonte-de-Abreu PS; Gama CS
J Clin Psychiatry; 2009 Oct; 70(10):1416-23. PubMed ID: 19906345
[TBL] [Abstract][Full Text] [Related]
16. Double-blind, placebo-controlled study of the efficacy of reboxetine and citalopram as adjuncts to atypical antipsychotics for negative symptoms of schizophrenia.
Usall J; López-Carrilero R; Iniesta R; Roca M; Caballero M; Rodriguez-Jimenez R; Oliveira C; Bernardo M; Corripio I; Sindreu SD; González Piqueras JC; Felipe AE; Fernandez de Corres B; Ibáñez A; Huerta R;
J Clin Psychiatry; 2014 Jun; 75(6):608-15. PubMed ID: 25004184
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine Add-On to Risperidone for Treatment of Negative Symptoms in Patients with Stable Schizophrenia: Randomized Double-Blind Placebo-Controlled Study.
Nikbakhat MR; Arabzadeh S; Zeinoddini A; Khalili Z; Rezaei F; Mohammadinejad P; Ghaleiha A; Akhondzadeh S
Pharmacopsychiatry; 2016 Jul; 49(4):162-9. PubMed ID: 26902281
[TBL] [Abstract][Full Text] [Related]
18. Therapeutic effects of cerebrolysin added to risperidone in patients with schizophrenia dominated by negative symptoms.
Xiao S; Xue H; Li G; Yuan C; Li X; Chen C; Wu HZ; Mitchell P; Zhang M
Aust N Z J Psychiatry; 2012 Feb; 46(2):153-60. PubMed ID: 22311531
[TBL] [Abstract][Full Text] [Related]
19. Initial severity of schizophrenia and efficacy of antipsychotics: participant-level meta-analysis of 6 placebo-controlled studies.
Furukawa TA; Levine SZ; Tanaka S; Goldberg Y; Samara M; Davis JM; Cipriani A; Leucht S
JAMA Psychiatry; 2015 Jan; 72(1):14-21. PubMed ID: 25372935
[TBL] [Abstract][Full Text] [Related]
20. Effect of divalproex combined with olanzapine or risperidone in patients with an acute exacerbation of schizophrenia.
Casey DE; Daniel DG; Wassef AA; Tracy KA; Wozniak P; Sommerville KW
Neuropsychopharmacology; 2003 Jan; 28(1):182-92. PubMed ID: 12496955
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
